Please watch and share our PSA on psychedelic risks and adverse events. It is important to have an evidence-based perspective on the risk/benefit profile of psychedelics:

📢 Now Recruiting: Research Study on Psilocybin for Depression in Early Alzheimer’s Disease. We are exploring whether psilocybin may help treat depression in individuals with Mild Cognitive Impairment (MCI) or early Alzheimer’s Disease. Participants receive psilocybin in a safe,

Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.

Do you struggle with chronic low back pain and depression? We are seeking individuals with chronic low back pain and co-occurring depression to see if psilocybin can help! Find out more and click the link below to apply! You may qualify if you. ✅ Are

Our research center is seeking a casual therapist to support cutting-edge studies on the therapeutic effects of psychedelics. Join a team at the forefront of mental health research. Apply below 👇.

Special event Wed 7/30! Dr. David Yaden will discuss the Archives project, where we set out to create the world’s largest database of psychedelic and psychedelic-like experiences, and why this matters! Email Brooklyn Arroyo (barroyo3@jh.edu) to join!

Reminiscing on all the great presentations and conversations we had at the Gordon Research Conference @GordonConf. Our faculty and postdocs were thrilled for the opportunity to present our recent findings. Special thanks to organizers @kwanalexc & @VVyazovskiy .@FredBarrettPhD,

RT @Katherine_Chg: Working on getting a bibliography of sorts for psychedelic ethics/philosophy papers together - sharing in case it comes….

We are seeking veterans who have experience with psilocybin and MDMA to fill out a brief 5-10 minute survey about their experiences. Click the link below to contribute to our research 👇

🚨 Call for Abstracts!.We're reviving the Lost Foundations of Psychedelic Science! This special issue of Psychedelic Medicine will explore forgotten studies, untranslated breakthroughs, and under-explored leads from the first era of psychedelic research. Read the open call here:.

Associate Director, Dr. Albert Garcia-Romeu shared his insights on psychedelic therapies for psychiatric disorders. He explains the science, shifting public perception, and potential for future FDA approval for these therapies.

RT @PraachiTiwari: Easily one of the best conferences I have attended so far! @GordonConf .Shout out to the leadership of @kwanalexc @VVyaz….

CPCR faculty David Yaden (@existwell) presented and participated in a panel on The Evolving Theory for Explaining Psychedelic Drug Action with Mark Geyer, Harriet de Wit, Franz Vollenweider, Bryan Roth, and Scott Thompson at #GRCPsychedelics.

RT @JRichardPhD: Amazing pre-clinical poster session at #GRCPsychedelics. Play the "Where's Waldo" of @JHPsychedelics postdocs and faculty.….

@FredBarrettPhD @ExistWell @PraachiTiwari @r_ehrenkranz @SeanPGoldy @NathalieRieser @zarmeen_z @JRichardPhD.

Thrilled to connect at the Neurobiology of Psychedelics Gordon Research Conference (@GordonConf) next week! CPCR researchers and fellow scientists will discuss wide range of topics, including preclinical and clinical research, drug discovery, and neuroplasticity.

Curious about psychedelic therapy? Join CPCR Associate Director, Dr. Albert Garcia-Romeu for the American Psychological Associations @APA Psychedelics: From Research to Clinical Practice training on Sept 13. Open to clinicians, researchers, and anyone eager to understand this.

‼️NEW STUDY FOR HEALTHY VOLUNTEERS‼️. Join our study at Johns Hopkins exploring how psilocybin—a naturally occurring compound in mushrooms—affects brain activity and function. Our study uses safe, noninvasive methods like EEG, fMRI, transcranial magnetic stimulation (TMS), and

Interested in becoming a psychedelic therapist? We’re seeking a full-time therapist to join our team and support innovative clinical trials exploring the therapeutic potential of psychedelics. Learn more and apply here: